Abstract:Cystic fibrosis (CF) is the most common terminal genetic illness amongst Caucasians. The median survival age has increased more dramatically over the last 25 years than for any other chronic illness,1 reaching 33.4 years by 2001, according to the American Cystic Fibrosis Foundation.2 The improvement in survival of CF patients has meant that the number of CF patients over the age of 18 years has increased from 8% in 1970 to 39.5% in 2001, in the USA.2 Exacerbations and hospitalization increase after the first ten years of CF patients’ lives, so patients and their families are familiar with many treatment effects and there is no reason why treatment should not be carried out in the patient’s home. According to data from the American Cystic Fibrosis Foundation for 2001, cultures of respiratory secretions were positive for Pseudomonas aeruginosa in 58.8% of cases, Staphylococcus aureus in 48%, Burkholderia cepacia in 3.1%, and Stenotrophomonas maltophilia in 8.4%. The only data available for Spain were collected in 1997 by the Federación Española contra la Fibrosis Quística. Only 15 CF units out of the whole country participated in this registry, which included a total of 823 patients with a median age of 15.1 years. Microbiological findings for these patients revealed that 37.06% were colonized with P aeruginosa, 35.60% with S aureus, 12.88% with Haemophilus influenzae, 2.79% with S malthophilia, 1.94% with B. cepacia, and 15.9% were not colonized by any germ. Intravenous (IV) antibiotic treatment is normally given to patients with moderate to severe respiratory exacerbations, or in cycles for patients chronically colonized by P aeruginosa, mucoid phenotype. In the latter case, adverse effects such as allergic reactions to antibiotics or increased bacterial resistance to antibiotics are more common. Nearly 2.5 times more adults than children currently elect home intravenous antibiotic treatment (HIVAT). According to data from the American Cystic Fibrosis Foundation, HIVAT use increased from 12% in 1990 to 20.3% in 2001.2 In order to discover the current situation of HIVAT for CF patients in Spain, the Sira Carrasco Foundation in aid of CF organized a consensus conference for specialists involved in CF, in Madrid on April 26, 2002. Two months prior to the conference, a letter was sent to all the CF units in Spain, saying that on the web page of the Sira Carrasco Foundation (www.fundacionfibrosisquistica.org) there was a questionnaire on HIVAT to be filled in and sent by Internet or post. The data from the questionnaires was statistically processed and the results discussed and consensus reached at the conference. Twenty CF units participated; among them they control 1230 patients, 740 younger than 18 years of age and 490 older. This document summarizes the consensus reached on different questions related to HIVAT and the resulting recommendations.

[Consensus conference: home intravenous antibiotic treatment for cystic fibrosis. The Sira Carrasco Foundation. 26 April 2002].

Recent advances in the understanding and management of ARDS

Definitions of Acute Respiratory Distress Syndrome: Present Recommendations and Challenges

Share First, Save Later: Performance of Self through Snapchat Stories

Acute respiratory distress syndrome: A review of ARDS across the life course

Management of the acute respiratory distress syndrome

The Acute Respiratory Distress Syndrome in 2013

Lymphocytic hypophysitis with normal pituitary function mimicking a pituitary adenoma: a case report and review of literature.

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes

Efficacy and safety of several common drugs in the treatment of acute respiratory distress syndrome: A systematic review and network meta-analysis

Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Acute respiratory distress syndrome: focusing on secondary injury

Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Innovations in protective mechanical ventilation for acute respiratory distress syndrome management

Re: Use of Osirix in developing a digital radiology teaching library.

Acute Respiratory Distress Syndrome and COVID-19: A Literature Review

Towards Simulation-Based Similarity of End User Browsing Processes

Conformational properties of the disaccharide building units of hyaluronan.

World summit against cancer for the new millennium: 4th February 2000 charter of Paris against cancer.